Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 23, 2025NEJM Evidence

Cendakimab in Adults and Adolescents with Eosinophilic Esophagitis

View Full Paper
Ask AI
Bookmark
Share

Authors

EDEvan S. DellonCCChristina M. CharriezSZSandra Zhang

Discussion

Loading...

Member takes

Overview

Phase 3 trial demonstrated significant symptom reduction and histologic response in EoE patients, suggesting cendakimab is a viable treatment option.

Key Points

  • Cendakimab significantly reduced dysphagia days in adults and adolescents with EoE at week 24 compared to placebo.
  • Histologic response was observed in 28.6% of patients treated with cendakimab versus just 2.2% with placebo at week 24.
  • The treatment regimen of cendakimab maintained efficacy at week 48, indicating sustained benefits for patients with EoE.
  • Adverse events occurred in 83.8% of those treated with cendakimab, aligning closely with placebo rates, suggesting a manageable safety profile.

Cite This Study

Dellon et al. (2025) studied this question.

synapsesocial.com/papers/68d440a6713b0b5dfea7ff9chttps://doi.org/10.1056/evidoa2500095
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rademikibart monotherapy for moderate-to-severe atopic dermatitis in a 1-year, randomized, phase II trial (S<i> <u>EASI</u> </i>DE CHINA): initial two-week dosing, followed by two-week or four-week dosing2025
  2. 2Monoclonal Antibodies for Eosinophilic Esophagitis and Gastritis2025
  3. 3Efficacy and Safety of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis2026
  4. 4Biologics for Eosinophilic Oesophagitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials2025
  5. 5Comparative short-term efficacy of Janus kinase 1 inhibitors and anti-interleukin-13 antibodies in atopic dermatitis: a retrospective cohort analysis based on real-world data2025